JP2016512493A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512493A5 JP2016512493A5 JP2015562425A JP2015562425A JP2016512493A5 JP 2016512493 A5 JP2016512493 A5 JP 2016512493A5 JP 2015562425 A JP2015562425 A JP 2015562425A JP 2015562425 A JP2015562425 A JP 2015562425A JP 2016512493 A5 JP2016512493 A5 JP 2016512493A5
- Authority
- JP
- Japan
- Prior art keywords
- ondansetron
- tablet
- hypromellose
- tablets
- seal coat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims 31
- 229960005343 ondansetron Drugs 0.000 claims 28
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 7
- 229960003943 hypromellose Drugs 0.000 claims 7
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 3
- 206010047700 Vomiting Diseases 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 230000003449 preventive effect Effects 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 1
- 239000012736 aqueous medium Substances 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 239000002702 enteric coating Substances 0.000 claims 1
- 238000009505 enteric coating Methods 0.000 claims 1
- 229920000831 ionic polymer Polymers 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- -1 sodium citrate anhydride Chemical class 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361782395P | 2013-03-14 | 2013-03-14 | |
| US61/782,395 | 2013-03-14 | ||
| PCT/IB2014/001633 WO2014181195A2 (en) | 2013-03-14 | 2014-03-14 | Antiemetic extended release solid dosage forms |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512493A JP2016512493A (ja) | 2016-04-28 |
| JP2016512493A5 true JP2016512493A5 (enExample) | 2017-04-20 |
| JP6282676B2 JP6282676B2 (ja) | 2018-02-21 |
Family
ID=51528070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562425A Active JP6282676B2 (ja) | 2013-03-14 | 2014-03-14 | 制吐作用のある徐放性固形製剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US9636305B2 (enExample) |
| EP (1) | EP2983664B1 (enExample) |
| JP (1) | JP6282676B2 (enExample) |
| KR (1) | KR102270521B1 (enExample) |
| CN (2) | CN112274489A (enExample) |
| AU (1) | AU2014264342B2 (enExample) |
| BR (1) | BR112015022398B1 (enExample) |
| CA (1) | CA2905553C (enExample) |
| CL (1) | CL2015002666A1 (enExample) |
| ES (1) | ES2946985T3 (enExample) |
| HK (1) | HK1223012A1 (enExample) |
| IL (1) | IL241580B (enExample) |
| MX (1) | MX378261B (enExample) |
| NZ (1) | NZ712159A (enExample) |
| PH (1) | PH12015502093B1 (enExample) |
| RU (1) | RU2679448C2 (enExample) |
| SG (1) | SG11201507450TA (enExample) |
| WO (2) | WO2014181195A2 (enExample) |
| ZA (1) | ZA201506961B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9636305B2 (en) | 2013-03-14 | 2017-05-02 | Redhill Biopharma Ltd. | Antiemetic extended release solid dosage forms |
| CA2941829C (en) * | 2014-03-11 | 2021-11-02 | Redhill Biopharma Ltd | Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms |
| CA2910865C (en) | 2014-07-15 | 2016-11-29 | Isa Odidi | Compositions and methods for reducing overdose |
| KR102300335B1 (ko) * | 2018-10-19 | 2021-09-10 | 주식회사 삼양홀딩스 | 아프레피탄트의 경구용 조성물 |
| US11969416B1 (en) | 2022-11-03 | 2024-04-30 | Lumos Pharma, Inc. | Compactable oral formulations of ibutamoren |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4720353A (en) | 1987-04-14 | 1988-01-19 | Richardson-Vicks Inc. | Stable pharmaceutical w/o emulsion composition |
| US6090411A (en) * | 1998-03-09 | 2000-07-18 | Temple University | Monolithic tablet for controlled drug release |
| US6733789B1 (en) | 1999-01-21 | 2004-05-11 | Biovail Laboratories, Inc. | Multiparticulate bisoprolol formulation |
| EP1239840B1 (en) | 1999-12-09 | 2005-04-06 | Alza Corporation | Antiviral medication |
| US6936275B2 (en) | 1999-12-20 | 2005-08-30 | Scolr, Inc. | Amino acid modulated extended release dosage form |
| WO2003024427A1 (en) | 1999-12-20 | 2003-03-27 | Temple University Of The Commonwealth System Of Higher Education | Tableted oral extended release dosage form |
| US20020044962A1 (en) | 2000-06-06 | 2002-04-18 | Cherukuri S. Rao | Encapsulation products for controlled or extended release |
| US6500457B1 (en) | 2000-08-14 | 2002-12-31 | Peirce Management, Llc | Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent |
| US20020172712A1 (en) | 2001-03-19 | 2002-11-21 | Alan Drizen | Antiemetic, anti-motion sustained release drug delivery system |
| GB0119012D0 (en) | 2001-08-03 | 2001-09-26 | Strakan Group Plc | Transdermal delivery of drugs |
| GB0129489D0 (en) * | 2001-12-10 | 2002-01-30 | Quadrant Healthcare Uk Ltd | Sustained-release compositions |
| US20050131045A1 (en) * | 2002-04-30 | 2005-06-16 | Judith Aronhime | Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them |
| US7704527B2 (en) * | 2002-10-25 | 2010-04-27 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
| JP2006516977A (ja) | 2003-01-13 | 2006-07-13 | ダイノゲン ファーマシューティカルズ，インコーポレイテッド | 悪心、嘔吐、レッチング、またはそれらの任意の組み合わせの治療方法 |
| ATE552838T1 (de) | 2003-11-14 | 2012-04-15 | Senju Pharma Co | Wässrige lösung mit aminoglykosid-antibiotikum und bromfenac |
| EP1787640A4 (en) * | 2004-04-30 | 2012-04-11 | Astellas Pharma Inc | GRAINED PHARMACEUTICAL COMPOSITION WITH TEMPORARY DELIVERY FOR ORAL ADMINISTRATION AND FAST-DECREASING INTRAORAL TABLET WITH THE COMPOSITION |
| AU2005319367B2 (en) * | 2004-12-20 | 2012-05-24 | Collegium Pharmaceutical, Inc. | Pharmaceutical compositions for sleep disorders |
| WO2007073702A2 (es) * | 2005-12-29 | 2007-07-05 | Osmotica Corp. | Comprimido multicapa con combinación de triple liberación |
| US20070190141A1 (en) | 2006-02-16 | 2007-08-16 | Aaron Dely | Extended release opiate composition |
| US20080004260A1 (en) * | 2006-06-29 | 2008-01-03 | Transcept Pharmaceuticals, Inc. | Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions |
| SI2051704T1 (sl) * | 2006-08-18 | 2012-08-31 | Evonik Roehm Gmbh | Farmacevtski sestavek s kontroliranim sproščanjem aktivne učinkovine za aktivne učinkovine z dobro topnostjo v vodi |
| CN100584319C (zh) | 2006-10-16 | 2010-01-27 | 北京科信必成医药科技发展有限公司 | 群孔释放渗透泵控释片及其制备方法 |
| CA2667207A1 (en) * | 2006-10-25 | 2008-05-02 | Mcneil-Ppc, Inc. | Ibuprofen composition |
| GB0624087D0 (en) | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril combination salt |
| US20100028420A1 (en) | 2006-12-22 | 2010-02-04 | 3M Innovative Properties Company | Controlled release composition and process |
| WO2009118763A1 (en) * | 2008-03-28 | 2009-10-01 | Panacea Biotec Limited | Multilayered pharmaceutical compositions and processes thereof |
| US20100196291A1 (en) | 2009-01-30 | 2010-08-05 | Laurence Halimi | Personal care sunscreen compositions having reduced eye irritation |
| WO2010100657A2 (en) | 2009-03-04 | 2010-09-10 | Fdc Limited | A novel oral controlled release dosage forms for water soluble drugs |
| US20110003005A1 (en) * | 2009-07-06 | 2011-01-06 | Gopi Venkatesh | Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions |
| RU2427389C2 (ru) * | 2009-10-09 | 2011-08-27 | Александр Владимирович Диковский | Фармацевтическая композиция для профилактики и лечения инфекционных и неинфекционных диарей |
| WO2011066289A1 (en) * | 2009-11-30 | 2011-06-03 | Eurand, Inc. | Ondansetron orally disintegrating tablet compositions for prevention of nausea and vomiting |
| RU2012131158A (ru) * | 2009-12-22 | 2014-01-27 | Эбботт Хелткеа Прайвит Лимитед | Фармацевтическая композиция с контролируемым высвобождением лекарственного средства |
| JP2013515782A (ja) | 2009-12-28 | 2013-05-09 | モノソル アールエックス リミテッド ライアビリティ カンパニー | オンダンセトロンを含む経口投与可能なフィルム製剤 |
| JP2013536832A (ja) | 2010-08-30 | 2013-09-26 | ルピン・リミテッド | ミルナシプランの制御放出医薬組成物 |
| US20120128730A1 (en) * | 2010-11-23 | 2012-05-24 | Nipun Davar | Compositions and methods for once-daily treatment of obsessive compulsive disorder with ondansetron |
| US9636305B2 (en) | 2013-03-14 | 2017-05-02 | Redhill Biopharma Ltd. | Antiemetic extended release solid dosage forms |
-
2014
- 2014-03-14 US US14/212,694 patent/US9636305B2/en active Active
- 2014-03-14 ES ES14795266T patent/ES2946985T3/es active Active
- 2014-03-14 AU AU2014264342A patent/AU2014264342B2/en active Active
- 2014-03-14 RU RU2015143993A patent/RU2679448C2/ru active
- 2014-03-14 CN CN202011222247.XA patent/CN112274489A/zh active Pending
- 2014-03-14 WO PCT/IB2014/001633 patent/WO2014181195A2/en not_active Ceased
- 2014-03-14 WO PCT/IB2014/001589 patent/WO2014184662A2/en not_active Ceased
- 2014-03-14 KR KR1020157028825A patent/KR102270521B1/ko active Active
- 2014-03-14 HK HK16111017.8A patent/HK1223012A1/zh unknown
- 2014-03-14 EP EP14795266.7A patent/EP2983664B1/en active Active
- 2014-03-14 SG SG11201507450TA patent/SG11201507450TA/en unknown
- 2014-03-14 JP JP2015562425A patent/JP6282676B2/ja active Active
- 2014-03-14 CN CN201480024401.9A patent/CN105530935A/zh active Pending
- 2014-03-14 CA CA2905553A patent/CA2905553C/en active Active
- 2014-03-14 MX MX2015012970A patent/MX378261B/es unknown
- 2014-03-14 US US14/212,954 patent/US20140271851A1/en not_active Abandoned
- 2014-03-14 NZ NZ712159A patent/NZ712159A/en not_active IP Right Cessation
- 2014-03-14 BR BR112015022398-2A patent/BR112015022398B1/pt active IP Right Grant
-
2015
- 2015-09-10 IL IL241580A patent/IL241580B/en active IP Right Grant
- 2015-09-14 CL CL2015002666A patent/CL2015002666A1/es unknown
- 2015-09-14 PH PH12015502093A patent/PH12015502093B1/en unknown
- 2015-09-18 ZA ZA2015/06961A patent/ZA201506961B/en unknown
-
2017
- 2017-03-22 US US15/466,214 patent/US20170189340A1/en not_active Abandoned
- 2017-08-16 US US15/678,386 patent/US20180028452A1/en not_active Abandoned
-
2020
- 2020-07-01 US US16/918,538 patent/US20200330392A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL298998B2 (en) | Pharmaceutical formulations of a hif hydroxylase inhibitor | |
| MX2015011896A (es) | Formulacion de liberacion sostenida de mosapride que proporciona efectos farmacologicos y clinicos con administracion una vez al dia. | |
| JP2006505566A5 (enExample) | ||
| JP2013511507A5 (enExample) | ||
| JP2016512493A5 (enExample) | ||
| JP2016523846A5 (enExample) | ||
| JP2016504384A5 (enExample) | ||
| JP2012144577A5 (enExample) | ||
| IL292262B2 (en) | Formulation of an oral administration form of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid | |
| JP2014533656A5 (enExample) | ||
| JP2009517466A5 (enExample) | ||
| US20150140084A1 (en) | Acid resistant banding solution for two piece hard capsules | |
| JP2008519070A5 (enExample) | ||
| JP2012167125A5 (enExample) | ||
| JP2019530706A5 (enExample) | ||
| JP2018118936A (ja) | 腸溶層破損防止用組成物 | |
| JP2019218379A5 (enExample) | ||
| EP2740471B1 (en) | Oral pharmaceutical composition comprising dabigatran etexilate | |
| JP2015531749A5 (enExample) | ||
| JP2010538062A5 (enExample) | ||
| CN102225202A (zh) | 一种包含阿司匹林和质子泵抑制剂的复方制剂 | |
| CN106794149A (zh) | 含ω‑3脂肪酸酯和他汀类的口服给药复合制剂 | |
| JP2018039810A5 (enExample) | ||
| RU2015143993A (ru) | Твердые лекарственные формы, обладающие противорвотным действием, с замедленным высвобождением | |
| ES2663357T3 (es) | Formulaciones de mazindol |